Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a US-based biotechnology company, announced on Thursday that it has filed an application with the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for ImmCelz(CELZ-100) platform intended to treat Brittle Type 1 Diabetes.
The ImmCelz (CELZ-100) immunotherapy product utilises the company's cell-free system, which has previously been validated to supercharge the patient's own cells to treat a number of immune disorders.
The company said that ImmCelz therapy, when co-administered with islet cells (PHPI), is a promising approach to overcoming transplant rejection in patients with brittle diabetes. Regulatory T cells, or Tregs, play a critical role in maintaining immune tolerance and suppressing alloreactive T cells and innate immune cells that contribute to islet transplant rejection. Several preclinical and clinical studies have demonstrated the efficacy and safety of immune therapy in promoting islet transplant survival, and it offers several advantages over other immunosuppressive therapies. The use of the ImmCelz platform with human Islet cell transplantation has been assigned its own designation as CELZ-101.
The FDA's Office of Orphan Drug Products grants orphan status to support the development of medicines for rare disorders that affect fewer than 200,000 people in the US Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees, and tax credits for qualified clinical trials.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes